Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper

Simon Stern; Satarupa Chaudhuri; Mark Drayson; Sarah Henshaw; Kamaraj Karunanithi; Fenella Willis; Haemato-Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum

doi:10.1111/bjh.18866

Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper

Br J Haematol. 2023 Aug;202(4):734-744. doi: 10.1111/bjh.18866. Epub 2023 May 18.

Authors

Simon Stern¹, Satarupa Chaudhuri², Mark Drayson³, Sarah Henshaw⁴, Kamaraj Karunanithi⁵, Fenella Willis⁶; Haemato-Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum

Affiliations

¹ Epsom and St Helier University Hospitals NHS Trust, Sutton, UK.
² Pennine Acute Hospitals NHS Trust, Bury, UK.
³ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁴ Nottingham University Hospitals NHS Trust, Nottingham, UK.
⁵ University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
⁶ St George's University Hospitals NHS Foundation Trust, London, UK.

PMID: 37587091
DOI: 10.1111/bjh.18866

Abstract

This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.

Keywords: MGCS; MGUS; monoclonal gammopathy of clinical significance; monoclonal gammopathy of undetermined significance; screening for MGUS.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Clinical Relevance
Hematology*
Humans
Monoclonal Gammopathy of Undetermined Significance* / diagnosis
Monoclonal Gammopathy of Undetermined Significance* / therapy